Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 2;16(11):1548.
doi: 10.3390/ph16111548.

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

Stephanie L Gu  1   2 , Tara Maier  1 , Andrea P Moy  3 , Stephen Dusza  1 , David M Faleck  4   5 , Neil J Shah  5   6 , Mario E Lacouture  1   2
Affiliations

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

Stephanie L Gu et al. Pharmaceuticals (Basel). .

Abstract

Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype. We report the use of ustekinumab as a therapeutic option. Methods: Patients at Memorial Sloan Kettering Cancer Center, New York, who received immune checkpoint inhibitors and were treated with ustekinumab or had the keywords "ustekinumab" or "Stelara" in their clinical notes between 1 March 2017 and 1 December 2022 were retrospectively identified via a database query. Documentation from initial and follow-up visits was manually reviewed, and response to ustekinumab was categorized into complete cutaneous response (CcR, decrease to CTCAE grade 0), partial cutaneous response (PcR, any decrease in CTCAE grade exclusive of decrease to grade 0), and no cutaneous response (NcR, no change in CTCAE grade or worsening). Labs including complete blood count (CBC), cytokine panels, and IgE were obtained in a subset of patients as standard of care. Skin biopsies were reviewed by a dermatopathologist. Results: Fourteen patients with psoriasiform (85.7%), maculopapular (7.1%), and pyoderma gangrenosum (7.1%) ircAEs were identified. Ten (71.4%) receiving ustekinumab had a positive response to treatment. Among these 10 responders, 4 (40%) demonstrated partial cutaneous response and 6 (60%) demonstrated complete cutaneous resolution. Six patients (42.9%) experienced interruptions to their checkpoint inhibitor treatment as a result of intolerable ircAEs, and following ircAE management with ustekinumab, two (33.3%) were successfully rechallenged with their checkpoint inhibitors. On histopathology, patients primarily had findings of interface or psoriasiform dermatitis. No patients reported an adverse event related to ustekinumab. Conclusions: Ustekinumab showed a benefit in a subset of patients with psoriasiform/lichenoid ircAEs. No safety signals were identified. However, further prospective randomized controlled trials are needed to confirm our findings.

Keywords: biologics; dermatologic adverse events; immune-related adverse events; immune-related cutaneous adverse events; ustekinumab.

PubMed Disclaimer

Conflict of interest statement

S.G., T.M., A.M., and S.D. have no disclosures to report. D.M.F. has received consulting fees from AzurRx, Equillium, Gilead, Janssen, Mallinckrodt Pharmaceuticals, and OnQuality Pharmaceuticals. NJS is a Speaker/Travel Consultant for Merk, Exelixis, Graticule, MedNet, and DAVA Oncology and receives research funding from Aravive and Exelixis. M.E.L. has a consultant role with Johnson and Johnson, Novocure, QED, Bicara, Janssen, Novartis, F. Hoffmann-LaRoche AG, EMD Serono, AstraZeneca, Innovaderm, Deciphera, DFB, Azitra, Kintara, RBC/La Roche Posay, Trifecta, Varsona, Genentech, Loxo, Seattle Genetics, Lutris, On Quality, Azitra, Roche, Oncoderm, NCODA, and Apricity. M.E.L. receives research funding from Lutris, Paxman, Novocure, J&J, US Biotest, OQL, Novartis, and AstraZeneca.

Figures

Figure 1
Figure 1
Representative clinical image of patient with palmoplantar psoriasis who received treatment with UST.
Figure 2
Figure 2
Swimmer’s plot of the time in therapy for both ICB therapy (colored bars) and ustekinumab (black bars), along with the timing of specific events within the treatment the course (n = 14). NcR= cutaneous non-responder to ustekinumab, cR = cutaneous responder to ustekinumab, IrcAE = immune-related cutaneous adverse event, CcR = complete cutaneous response to ustekinumab, PcR = partial cutaneous response to ustekinumab.
Figure 3
Figure 3
Two-way bar chart of the proportion of patients on specific treatments prior to and concurrent with ustekinumab (n = 14).
See this image and copyright information in PMC

References

    1. Gandhi L., Rodríguez-Abreu D., Gadgeel S., Esteban E., Felip E., De Angelis F., Domine M., Clingan P., Hochmair M.J., Powell S.F., et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018;378:2078–2092. doi: 10.1056/NEJMoa1801005. - DOI - PubMed
    1. Hellmann M.D., Paz-Ares L., Bernabe Caro R., Zurawski B., Kim S.W., Carcereny Costa E., Park K., Alexandru A., Lupinacci L., de la Mora Jimenez E., et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2019;381:2020–2031. doi: 10.1056/NEJMoa1910231. - DOI - PubMed
    1. Motzer R., Alekseev B., Rha S.Y., Porta C., Eto M., Powles T., Grünwald V., Hutson T.E., Kopyltsov E., Méndez-Vidal M.J., et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N. Engl. J. Med. 2021;384:1289–1300. doi: 10.1056/NEJMoa2035716. - DOI - PubMed
    1. Shah N.J., Sura S.D., Shinde R., Shi J., Singhal P.K., Robert N.J., Vogelzang N.J., Perini R.F., Motzer R.J. Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era. Eur. Urol. Open Sci. 2023;49:110–118. doi: 10.1016/j.euros.2022.12.015. - DOI - PMC - PubMed
    1. Wolchok J.D., Chiarion-Sileni V., Gonzalez R., Rutkowski P., Grob J.J., Cowey C.L., Lao C.D., Wagstaff J., Schadendorf D., Ferrucci P.F., et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2017;377:1345–1356. doi: 10.1056/NEJMoa1709684. - DOI - PMC - PubMed

LinkOut - more resources